rearrangements and BRAF mutations to the list of actionable biomarkers that need to be negative before administering immunotherapy. 23 Patients with metastatic NSCLC and PD-L1 expression levels of ≥50%—but who also have a targetable driver oncogene molecular
Search Results
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020
Featured Updates to the NCCN Guidelines
David S. Ettinger, Douglas E. Wood, Charu Aggarwal, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D’Amico, Thomas J. Dilling, Michael Dobelbower, Scott Gettinger, Ramaswamy Govindan, Matthew A. Gubens, Mark Hennon, Leora Horn, Rudy P. Lackner, Michael Lanuti, Ticiana A. Leal, Jules Lin, Billy W. Loo Jr, Renato G. Martins, Gregory A. Otterson, Sandip P. Patel, Karen L. Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, James Stevenson, Scott J. Swanson, Kurt W. Tauer, Stephen C. Yang, Kristina Gregory, OCN, and Miranda Hughes
John P. Sherbeck, Lili Zhao, and Richard W. Lieberman
features associated with lymph node count . Dis Colon Rectum 2013 ; 56 : 1028 – 1035 . 11. Berg M Guriby M Nordgard O . Influence of microsatellite instability and KRAS and BRAF mutations on lymph node harvest in stage I-III colon cancers
Van K. Morris and Cathy Eng
immunity . Cancer Res 2005 ; 65 : 1089 – 1096 . 22. Robert C Long GV Brady B . Nivolumab in previously untreated melanoma without BRAF mutation . N Engl J Med 2015 ; 372 : 320 – 330 . 23. Motzer RJ Escudier B McDermott DF
Zhong Ye, Chun Wang, Limin Guo, Juan P. Palazzo, Zhixing Han, Yinzhi Lai, Jing Jiang, James A. Posey, Atrayee Basu Mallick, Bingshan Li, Li Jiang, and Hushan Yang
] . JAMA Oncol , doi: 10.1001/jamaoncol.2016.3797 25. Taieb J Kourie HR Emile JF . Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational status . JAMA Oncol 2018 ; 4 : e173695
Daenielle Lang and Kristen K. Ciombor
, Köhne CH , Láng I , Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status . J Clin Oncol 2011
Yoshikuni Kawaguchi, Scott Kopetz, Heather A. Lillemoe, Hyunsoo Hwang, Xuemei Wang, Ching-Wei D. Tzeng, Yun Shin Chun, Thomas A. Aloia, and Jean-Nicolas Vauthey
limitation, however, the patient population was large enough for us to perform robust multivariable analyses. Third, we did not assess BRAF mutation status because BRAF is mutated in only 1% to 6% of patients, as shown in surgical series. 28 A final
Daniel G. Coit, Robert Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson III, Adil Daud, Raza A. Dilawari, Dominick DiMaio, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr., Mark C. Kelley, Nikhil I. Khushalani, Ragini R. Kudchadkar, Julie R. Lange, Anne Lind, Mary C. Martini, Anthony J. Olszanski, Scott K. Pruitt, Merrick I. Ross, Susan M. Swetter, Kenneth K. Tanabe, John A. Thompson, Vijay Trisal, and Marshall M. Urist
BRAF mutation. The Cobas 4800 BRAF V600 mutation test, a companion diagnostic test to determine the tumor mutational status, received approval along with the agent. The panel added vemurafenib to the list of available systemic treatments for patients
David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D’Amico, Malcolm DeCamp, Thomas J. Dilling, Jonathan Dowell, Scott Gettinger, Travis E. Grotz, Matthew A. Gubens, Aparna Hegde, Rudy P. Lackner, Michael Lanuti, Jules Lin, Billy W. Loo Jr., Christine M. Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Thomas Ng, Gregory A. Otterson, Jose M. Pacheco, Sandip P. Patel, Gregory J. Riely, Jonathan Riess, Steven E. Schild, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C. Yang, Edwin Yau, Kristina Gregory, and Miranda Hughes
progression on either alectinib, brigatinib, or ceritinib. Oral Agents That Inhibit BRAF Mutations BRAF (v-Raf murine sarcoma viral oncogene homolog B) is a serine/threonine kinase that is part of the MAP/ERK signaling pathway. The BRAF V600E
Melanoma, Version 2.2013
Featured Updates to the NCCN Guidelines
Daniel G. Coit, Robert Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson III, Adil Daud, Dominick DiMaio, Martin D. Fleming, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr., Mark C. Kelley, Nikhil I. Khushalani, Ragini R. Kudchadkar, Julie R. Lange, Anne Lind, Mary C. Martini, Anthony J. Olszanski, Scott K. Pruitt, Merrick I. Ross, Susan M. Swetter, Kenneth K. Tanabe, John A. Thompson, Vijay Trisal, Marshall M. Urist, Nicole McMillian, and Maria Ho
treatment of BRAF mutation–positive unresectable or metastatic melanoma. Another phase II trial in 132 previously treated patients reported an overall response rate of 53% and a median survival of 15.9 months. 25 Secondary skin lesions were detected in 26
Philip E. Lammers and Leora Horn
available. Other potential targets have been identified, such as c-ros oncogene 1 (ROS1) gene fusions and BRAF mutations, and clinical trials using targeted agents are ongoing. Alternative targets continue to be investigated, one of which is angiogenesis
